Crescent Biopharma, Inc. (CBIO)
Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing innovative cancer therapy candidates. Their pipeline includes bispecific antibodies and strategic partnerships for oncology therapeutics.
Company Overview
Crescent Biopharma pioneers next-generation cancer therapies with its novel bispecific antibody pipeline and strategic collaborations, offering a compelling investment in the evolving oncology landscape and positioning them as a key player in innovative cancer treatments.
Investment Thesis
Crescent Biopharma presents a compelling investment opportunity due to its innovative pipeline of cancer therapy candidates, particularly the CR-001 bispecific antibody targeting both PD-1 and VEGF. The strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. further strengthens the company's position by providing access to resources and expertise for development and commercialization. With a market capitalization of $0.26 billion, Crescent Biopharma offers potential for significant growth as its pipeline progresses through clinical trials. The high gross margin of 94.8% indicates strong potential profitability upon successful commercialization of its products. Key value drivers include positive clinical trial results for CR-001 and subsequent regulatory approvals, which could drive substantial revenue growth and increase shareholder value. The company's focus on novel combinations and strategic collaborations enhances its competitive advantage in the oncology market.
Key Highlights
- Market capitalization of $0.26 billion, indicating the company's current valuation in the market.
- Gross margin of 94.8%, reflecting the company's ability to efficiently manage production costs.
- Strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., enhancing development and commercialization capabilities.
- Pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody targeting solid tumors.
- Negative P/E ratio of -15.44, typical for biotech companies investing heavily in R&D and not yet profitable.
Competitors
Strengths
- Innovative bispecific antibody technology.
- Strategic partnership with Sichuan Kelun-Biotech.
- Experienced management team with expertise in oncology.
- Strong intellectual property portfolio.
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on the success of its lead candidate, CR-001.
- Lack of established commercial infrastructure.
- Negative profit margin.
Catalysts
- Upcoming: Initiation of Phase 2 clinical trials for CR-001 in Q3 2026.
- Ongoing: Enrollment of patients in ongoing Phase 1 clinical trials for CR-001.
- Upcoming: Presentation of clinical trial data at major oncology conferences in Q4 2026.
- Ongoing: Continued progress in the development of CR-002 and CR-003.
Risks
- Potential: Clinical trial failures for CR-001 or other pipeline candidates.
- Potential: Regulatory delays or rejection of marketing applications.
- Ongoing: Competition from established pharmaceutical companies and other emerging biotech firms.
- Potential: Dependence on strategic partnerships for funding and development.
- Ongoing: High cash burn rate and need for additional financing.
Growth Opportunities
- Clinical Trial Success of CR-001: Positive results from clinical trials for CR-001, the company's lead bispecific antibody candidate, could significantly increase its market value. The global market for bispecific antibodies is projected to reach $12.8 billion by 2030. Successful trials would pave the way for regulatory approvals and commercialization, driving revenue growth and attracting further investment. This growth opportunity is contingent on ongoing clinical trials and regulatory timelines.
- Expansion of Strategic Partnerships: Forming additional strategic partnerships with other pharmaceutical or biotechnology companies could provide access to new technologies, funding, and market opportunities. Collaborations can accelerate the development and commercialization of Crescent Biopharma's pipeline and expand its reach in the global oncology market. The timeline for securing new partnerships is dependent on ongoing negotiations and market conditions.
- Development of Novel Combination Therapies: Leveraging the partnership with Sichuan Kelun-Biotech to develop novel combination therapies could address unmet medical needs in oncology and create new revenue streams. Combination therapies often demonstrate improved efficacy and can overcome resistance mechanisms. The market for combination therapies is expected to grow as personalized medicine becomes more prevalent. Development timelines depend on research and clinical trial progress.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as China and India, could provide access to a large patient population and drive revenue growth. These markets are experiencing rapid economic growth and increasing healthcare spending. Crescent Biopharma's partnership with Sichuan Kelun-Biotech provides a strategic advantage for entering the Chinese market. The timeline for geographic expansion depends on regulatory approvals and market entry strategies.
- Advancement of CR-002 and CR-003: Progressing the development of CR-002 and CR-003, the company's other pipeline candidates, could diversify its product portfolio and reduce reliance on CR-001. These candidates may target different cancer types or pathways, expanding the company's addressable market. Successful development and commercialization of these candidates would contribute to long-term revenue growth and shareholder value. The timeline for advancing these candidates depends on preclinical and clinical trial progress.
Opportunities
- Positive clinical trial results for CR-001.
- Expansion into new therapeutic areas within oncology.
- Further strategic partnerships and collaborations.
- Increasing demand for innovative cancer therapies.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays in drug approval.
- Clinical trial failures.
- Patent challenges and intellectual property disputes.
Competitive Advantages
- Proprietary bispecific antibody technology.
- Strategic partnership with Sichuan Kelun-Biotech.
- Strong intellectual property portfolio protecting its pipeline candidates.
About
Crescent Biopharma, Inc. is a biotechnology company dedicated to the discovery and development of innovative cancer therapeutics. The company's primary focus is on creating novel treatments for solid tumors, leveraging cutting-edge science to address unmet medical needs in oncology. Crescent Biopharma's pipeline features a range of cancer therapy candidates, including CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody designed to target solid tumors by simultaneously blocking PD-1 and VEGF pathways, enhancing immune response and inhibiting angiogenesis. In addition to CR-001, the company is also developing CR-002 and CR-003, further expanding its portfolio of potential cancer treatments. Crescent Biopharma is headquartered in Waltham, Massachusetts, and operates with a team of 41 employees focused on advancing its research and development programs. The company has established a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a collaboration aimed at accelerating the development and commercialization of oncology therapeutics, including novel combinations. This partnership enhances Crescent Biopharma's capabilities and expands its reach in the global oncology market, positioning the company for future growth and success in the biotechnology industry.
What They Do
- Researches and develops cancer therapy candidates.
- Develops bispecific antibodies for treating solid tumors.
- Focuses on innovative treatments for oncology.
- Partners with other companies for development and commercialization.
- Targets unmet medical needs in the cancer treatment landscape.
- Aims to improve patient outcomes through novel therapeutic approaches.
Business Model
- Develops and patents novel cancer therapy candidates.
- Out-licenses or co-develops its therapies with strategic partners.
- Generates revenue through milestone payments and royalties on commercialized products.
Industry Context
Crescent Biopharma operates within the competitive biotechnology industry, which is characterized by rapid innovation and significant investment in research and development. The global oncology market is experiencing substantial growth, driven by an aging population and increasing prevalence of cancer. Bispecific antibodies, like CR-001, represent a promising therapeutic approach, offering the potential to simultaneously target multiple pathways involved in tumor growth and immune evasion. Crescent Biopharma's strategic partnership with Sichuan Kelun-Biotech positions it to capitalize on the growing demand for innovative cancer therapies, while facing competition from established pharmaceutical companies and other emerging biotech firms.
Key Customers
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients suffering from solid tumors who need innovative treatment options.
- Healthcare providers looking for effective cancer therapies.
Financials
Chart & Info
Price Chart
Crescent Biopharma, Inc. (CBIO) stock price: $9.72 (+0.00, +0.00%)
Why Bull
- •Crescent Bio's recent insider buying suggests those in the know see value, boosting confidence.
- •The community's generally optimistic outlook on CBIO's pipeline hints at potential future gains.
- •Market perception seems to be shifting positively, with increased media coverage about their clinical trials.
- •Recent developments in the biopharma sector could create a favorable environment for CBIO's growth, similar to the tailwinds that propelled Moderna during the pandemic.
Why Bear
- •Recent insider selling, if any, could signal concerns about the company's near-term prospects.
- •Negative community sentiment regarding potential regulatory hurdles might dampen investor enthusiasm.
- •Market perception might be overly optimistic, overlooking potential risks in CBIO's drug development process.
- •The biopharma sector is highly competitive, and CBIO faces significant challenges from larger, established players, like the headwinds faced by smaller EV companies against Tesla.
Latest News
-
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga · Feb 19, 2026
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Feb 19, 2026
-
Crescent Biopharma Announces Grants of Inducement Awards
Yahoo! Finance: CBIO News · Feb 19, 2026
-
Crescent Biopharma Announces Grants of Inducement Awards
GlobeNewswire · Feb 19, 2026
Technical Analysis
Rationale
AI-generated technical analysis for CBIO including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Crescent Biopharma, Inc. (CBIO) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for CBIO.
Make a Prediction
Set your price target for Crescent Biopharma, Inc. (CBIO), choose a timeframe, and track your prediction accuracy.
Current price: $9.72
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBIO.
Price Targets
Wall Street price target analysis for CBIO.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 10/100
Gross margin of 94.8% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Limited cash of $35M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 1.08% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates CBIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Grants of Inducement Awards
Frequently Asked Questions
What does Crescent Biopharma, Inc. do?
Crescent Biopharma, Inc. is a biotechnology company focused on researching and developing innovative cancer therapy candidates. Their lead candidate, CR-001, is a proprietary anti-PD-1/anti-VEGF bispecific antibody designed to treat solid tumors. The company's business model revolves around developing and patenting novel cancer therapies, out-licensing or co-developing these therapies with strategic partners, and generating revenue through milestone payments and royalties upon successful commercialization. Crescent Biopharma aims to address unmet medical needs in oncology by providing new and effective treatment options for patients.
Is CBIO stock a good buy?
CBIO stock presents a speculative investment opportunity with high potential upside and significant risks. The company's innovative pipeline, particularly CR-001, offers potential for substantial growth if clinical trials are successful and regulatory approvals are obtained. The strategic partnership with Sichuan Kelun-Biotech enhances the company's development and commercialization capabilities. However, the company's negative P/E ratio of -15.44 and negative profit margin of -183.1% indicate that it is not yet profitable and relies on external funding. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in CBIO.
What are the main risks for CBIO?
The main risks for CBIO include clinical trial failures, regulatory delays, competition from established pharmaceutical companies, dependence on strategic partnerships, and the need for additional financing. Clinical trial failures for CR-001 or other pipeline candidates could significantly impact the company's value and prospects. Regulatory delays or rejection of marketing applications could delay or prevent the commercialization of its products. Competition from larger pharmaceutical companies with greater resources could limit its market share. Dependence on strategic partnerships for funding and development exposes the company to potential disruptions if these partnerships are terminated or altered. The company's high cash burn rate and need for additional financing could dilute existing shareholders or limit its ability to execute its growth strategy.
Is CBIO a good stock to buy?
Whether CBIO is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the CBIO MoonshotScore?
The MoonshotScore for CBIO is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is CBIO data updated?
CBIO stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CBIO is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for CBIO?
Growth catalysts for Crescent Biopharma, Inc. (CBIO) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Crescent Biopharma, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are CBIO's main competitors?
Crescent Biopharma, Inc. (CBIO) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CBIO has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about CBIO?
Wall Street analyst coverage for CBIO includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is CBIO's market cap?
Market capitalization (market cap) for CBIO is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CBIO's current market cap alongside enterprise value and other valuation metrics.
How has CBIO stock performed recently?
CBIO's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CBIO's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in CBIO?
Key risk categories for CBIO include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CBIO's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling CBIO?
Insider trading activity for CBIO tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is CBIO a good stock for beginners?
Crescent Biopharma, Inc. (CBIO) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is CBIO for first-time investors?
Every stock carries risk, including Crescent Biopharma, Inc. (CBIO). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CBIO.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update may impact financial metrics.
- Future clinical trial results are uncertain and could affect the company's prospects.